Core Points - Eli Lilly plans to invest $5 billion in a manufacturing facility in Virginia, marking the first of four new plants in the U.S. [1] - The investment is part of a strategy to expand domestic production and mitigate potential tariff risks [1] - The new facility will produce active pharmaceutical ingredients for cancer, autoimmune, and other advanced therapies, expected to be completed in five years [1] Company Investment Plans - Eli Lilly has committed to investing at least $27 billion to build four new manufacturing bases in the U.S. to address potential drug import tariffs [1] - Since 2020, the company has pledged $50 billion for capital expansion [1] Job Creation - The Virginia facility will create over 650 skilled jobs, including engineers and scientists, along with 1,800 construction jobs [1] - The company plans to announce the locations of the remaining three U.S. plants later this year, with production expected to start in all four facilities within five years [1]